Acetylsalicylic acid/dipyridamole explained

The combination drug acetylsalicylic acid/dipyridamole (trade names Aggrenox, Asasantin) is a drug combination of:[1]

The combination acts as an extended release formulation and is primarily used for platelet inhibition in patients suffering, or at risk from, acute coronary events and stroke.[2] Its use has been shown to be better than the use of either dipyridamole or aspirin alone.[3]

Notes and References

  1. http://www.fass.se/LIF/produktfakta/artikel_produkt.jsp?NplID=19971212000035&DocTypeID=7&UserTypeID=2 FASS (the Swedish official drug catalog) > Asasantin
  2. Malinin AI, Eisert RM, Atar D, Barkagan Z, Serebruany VL . 71396361. Aggrenox (Extended-Release Dipyridamole and Low-Dose Aspirin in Combination): Protecting Platelets from Excessive Activation in Patients with Vascular Events. Heart Drug. 2002. 2. 2. 93–104. 10.1159/000063427.
  3. Serebruany VL, Malinin AI, Sane DC, Jilma B, Takserman A, Atar D, Hennekens CH . Magnitude and time course of platelet inhibition with Aggrenox and Aspirin in patients after ischemic stroke: the AGgrenox versus Aspirin Therapy Evaluation (AGATE) trial . European Journal of Pharmacology . 499 . 3 . 315–24 . September 2004 . 15381054 . 10.1016/j.ejphar.2004.07.114 .